Genetic predictors of response to photodynamictherapy

Francesco Parmeggiani, Donato Gemmati, Ciro Costagliola, Francesco Semeraro, Paolo Perri, Sergio Dangelo, Mario R. Romano, Katia De Nadai, Adolfo Sebastiani, Carlo Incorvaia

Research output: Contribution to journalArticle

Abstract

In Western countries, therapeutic management of patients affected by choroidal neovascularization (CNV) secondary to different typologies of macular degeneration represents a major health care problem. Age-related macular degeneration is the disease most frequently associated with CNV development. Schematically, CNVs can be distinguished into classic and occult subtypes, which are characterized by variable natural history and different responsiveness to some therapeutic procedures. At present, the dramatic vision loss due to CNV can be mainly treated by two interventional strategies, which are utilizable in either single or combined modalities: photodynamic therapy with verteporfin (PDT-V), and intravitreal administration of drugs acting against vascular endothelial growth factor. The combined use of PDT-V and anti-angiogenic drugs represents one of the most promising strategies against neovascular macular degeneration, but it unavoidably results in an expensive increase in health resource utilization. However, the positive data from several studies serve as a basis for reconsidering the role of PDT-V, which has undergone a renaissance prompted by the need for a more rational therapeutic approach toward CNV. New pharmacogenetic knowledge of PDT-V points to exploratory prospects to optimize the clinical application of this intriguing photothrombotic procedure. In fact, a Medline search provides data regarding the role of several single nucleotide polymorphisms (SNPs) as genetic predictors of CNV responsiveness to PDT-V. Specifically, correlations between SNPs and different levels of PDT-V efficacy have been detected by examining the gene variants influencing (i) thrombo-coagulative pathways, i.e. methylenetetrahydrofolate reductase (MTHFR) 677C>T (rs1801133), factor V (F5) 1691G>A (rs6025), prothrombin (F2) 20210G>A (rs1799963), and factor XIII-A (F13A1) 185G>T (rs5985); (ii) complement activation andor inflammatory processes, i.e. complement factor H (CFH) 1277T>C (rs1061170), high-temperature requirement factor A1 (HTRA1) promoter -512G>A (rs11200638), and two variants of the C-reactive protein (CRP) gene (rs2808635 and rs876538); and (iii) production and bioavailability of vascular endothelial growth factor (VEGFA -2578C>A rs699947 and rs2146323). This article critically evaluates both the clinical plausibility and the opportunity to utilize the most important SNP-response interactions of PDT-V for an effective upgrade of the current anti-CNV therapeutic scenario. In addition, the pharmacogenetics of a very severe post-PDT-V adverse event, i.e. a decrease in acute vision, is briefly discussed. A comprehensive appraisal of the findings reviewed in this article should be carefully considered to design future trials aimed at verifying (after proper genotypic stratification of the enrolled patients) whether these innovative pharmacogenetic approaches will be able to improve the multifaceted interventional management of neovascular macular degeneration.

Original languageEnglish
Pages (from-to)195-210
Number of pages16
JournalMolecular Diagnosis and Therapy
Volume15
Issue number4
DOIs
Publication statusPublished - 2011

Fingerprint

Photochemotherapy
Choroidal Neovascularization
Macular Degeneration
Pharmacogenetics
Single Nucleotide Polymorphism
Vascular Endothelial Growth Factor A
Factor XIII
Complement Factor H
Methylenetetrahydrofolate Reductase (NADPH2)
Combined Modality Therapy
Angiogenesis Inhibitors
Factor V
Health Resources
Complement Activation
Prothrombin
Therapeutics
verteporfin
Natural History
C-Reactive Protein
Biological Availability

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Medicine(all)
  • Pharmacology

Cite this

Parmeggiani, F., Gemmati, D., Costagliola, C., Semeraro, F., Perri, P., Dangelo, S., ... Incorvaia, C. (2011). Genetic predictors of response to photodynamictherapy. Molecular Diagnosis and Therapy, 15(4), 195-210. https://doi.org/10.2165/11592270-000000000-00000

Genetic predictors of response to photodynamictherapy. / Parmeggiani, Francesco; Gemmati, Donato; Costagliola, Ciro; Semeraro, Francesco; Perri, Paolo; Dangelo, Sergio; Romano, Mario R.; De Nadai, Katia; Sebastiani, Adolfo; Incorvaia, Carlo.

In: Molecular Diagnosis and Therapy, Vol. 15, No. 4, 2011, p. 195-210.

Research output: Contribution to journalArticle

Parmeggiani, F, Gemmati, D, Costagliola, C, Semeraro, F, Perri, P, Dangelo, S, Romano, MR, De Nadai, K, Sebastiani, A & Incorvaia, C 2011, 'Genetic predictors of response to photodynamictherapy', Molecular Diagnosis and Therapy, vol. 15, no. 4, pp. 195-210. https://doi.org/10.2165/11592270-000000000-00000
Parmeggiani F, Gemmati D, Costagliola C, Semeraro F, Perri P, Dangelo S et al. Genetic predictors of response to photodynamictherapy. Molecular Diagnosis and Therapy. 2011;15(4):195-210. https://doi.org/10.2165/11592270-000000000-00000
Parmeggiani, Francesco ; Gemmati, Donato ; Costagliola, Ciro ; Semeraro, Francesco ; Perri, Paolo ; Dangelo, Sergio ; Romano, Mario R. ; De Nadai, Katia ; Sebastiani, Adolfo ; Incorvaia, Carlo. / Genetic predictors of response to photodynamictherapy. In: Molecular Diagnosis and Therapy. 2011 ; Vol. 15, No. 4. pp. 195-210.
@article{d9dbd080e93b4e1f927cb698a94b9d94,
title = "Genetic predictors of response to photodynamictherapy",
abstract = "In Western countries, therapeutic management of patients affected by choroidal neovascularization (CNV) secondary to different typologies of macular degeneration represents a major health care problem. Age-related macular degeneration is the disease most frequently associated with CNV development. Schematically, CNVs can be distinguished into classic and occult subtypes, which are characterized by variable natural history and different responsiveness to some therapeutic procedures. At present, the dramatic vision loss due to CNV can be mainly treated by two interventional strategies, which are utilizable in either single or combined modalities: photodynamic therapy with verteporfin (PDT-V), and intravitreal administration of drugs acting against vascular endothelial growth factor. The combined use of PDT-V and anti-angiogenic drugs represents one of the most promising strategies against neovascular macular degeneration, but it unavoidably results in an expensive increase in health resource utilization. However, the positive data from several studies serve as a basis for reconsidering the role of PDT-V, which has undergone a renaissance prompted by the need for a more rational therapeutic approach toward CNV. New pharmacogenetic knowledge of PDT-V points to exploratory prospects to optimize the clinical application of this intriguing photothrombotic procedure. In fact, a Medline search provides data regarding the role of several single nucleotide polymorphisms (SNPs) as genetic predictors of CNV responsiveness to PDT-V. Specifically, correlations between SNPs and different levels of PDT-V efficacy have been detected by examining the gene variants influencing (i) thrombo-coagulative pathways, i.e. methylenetetrahydrofolate reductase (MTHFR) 677C>T (rs1801133), factor V (F5) 1691G>A (rs6025), prothrombin (F2) 20210G>A (rs1799963), and factor XIII-A (F13A1) 185G>T (rs5985); (ii) complement activation andor inflammatory processes, i.e. complement factor H (CFH) 1277T>C (rs1061170), high-temperature requirement factor A1 (HTRA1) promoter -512G>A (rs11200638), and two variants of the C-reactive protein (CRP) gene (rs2808635 and rs876538); and (iii) production and bioavailability of vascular endothelial growth factor (VEGFA -2578C>A rs699947 and rs2146323). This article critically evaluates both the clinical plausibility and the opportunity to utilize the most important SNP-response interactions of PDT-V for an effective upgrade of the current anti-CNV therapeutic scenario. In addition, the pharmacogenetics of a very severe post-PDT-V adverse event, i.e. a decrease in acute vision, is briefly discussed. A comprehensive appraisal of the findings reviewed in this article should be carefully considered to design future trials aimed at verifying (after proper genotypic stratification of the enrolled patients) whether these innovative pharmacogenetic approaches will be able to improve the multifaceted interventional management of neovascular macular degeneration.",
author = "Francesco Parmeggiani and Donato Gemmati and Ciro Costagliola and Francesco Semeraro and Paolo Perri and Sergio Dangelo and Romano, {Mario R.} and {De Nadai}, Katia and Adolfo Sebastiani and Carlo Incorvaia",
year = "2011",
doi = "10.2165/11592270-000000000-00000",
language = "English",
volume = "15",
pages = "195--210",
journal = "Molecular Diagnosis and Therapy",
issn = "1177-1062",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Genetic predictors of response to photodynamictherapy

AU - Parmeggiani, Francesco

AU - Gemmati, Donato

AU - Costagliola, Ciro

AU - Semeraro, Francesco

AU - Perri, Paolo

AU - Dangelo, Sergio

AU - Romano, Mario R.

AU - De Nadai, Katia

AU - Sebastiani, Adolfo

AU - Incorvaia, Carlo

PY - 2011

Y1 - 2011

N2 - In Western countries, therapeutic management of patients affected by choroidal neovascularization (CNV) secondary to different typologies of macular degeneration represents a major health care problem. Age-related macular degeneration is the disease most frequently associated with CNV development. Schematically, CNVs can be distinguished into classic and occult subtypes, which are characterized by variable natural history and different responsiveness to some therapeutic procedures. At present, the dramatic vision loss due to CNV can be mainly treated by two interventional strategies, which are utilizable in either single or combined modalities: photodynamic therapy with verteporfin (PDT-V), and intravitreal administration of drugs acting against vascular endothelial growth factor. The combined use of PDT-V and anti-angiogenic drugs represents one of the most promising strategies against neovascular macular degeneration, but it unavoidably results in an expensive increase in health resource utilization. However, the positive data from several studies serve as a basis for reconsidering the role of PDT-V, which has undergone a renaissance prompted by the need for a more rational therapeutic approach toward CNV. New pharmacogenetic knowledge of PDT-V points to exploratory prospects to optimize the clinical application of this intriguing photothrombotic procedure. In fact, a Medline search provides data regarding the role of several single nucleotide polymorphisms (SNPs) as genetic predictors of CNV responsiveness to PDT-V. Specifically, correlations between SNPs and different levels of PDT-V efficacy have been detected by examining the gene variants influencing (i) thrombo-coagulative pathways, i.e. methylenetetrahydrofolate reductase (MTHFR) 677C>T (rs1801133), factor V (F5) 1691G>A (rs6025), prothrombin (F2) 20210G>A (rs1799963), and factor XIII-A (F13A1) 185G>T (rs5985); (ii) complement activation andor inflammatory processes, i.e. complement factor H (CFH) 1277T>C (rs1061170), high-temperature requirement factor A1 (HTRA1) promoter -512G>A (rs11200638), and two variants of the C-reactive protein (CRP) gene (rs2808635 and rs876538); and (iii) production and bioavailability of vascular endothelial growth factor (VEGFA -2578C>A rs699947 and rs2146323). This article critically evaluates both the clinical plausibility and the opportunity to utilize the most important SNP-response interactions of PDT-V for an effective upgrade of the current anti-CNV therapeutic scenario. In addition, the pharmacogenetics of a very severe post-PDT-V adverse event, i.e. a decrease in acute vision, is briefly discussed. A comprehensive appraisal of the findings reviewed in this article should be carefully considered to design future trials aimed at verifying (after proper genotypic stratification of the enrolled patients) whether these innovative pharmacogenetic approaches will be able to improve the multifaceted interventional management of neovascular macular degeneration.

AB - In Western countries, therapeutic management of patients affected by choroidal neovascularization (CNV) secondary to different typologies of macular degeneration represents a major health care problem. Age-related macular degeneration is the disease most frequently associated with CNV development. Schematically, CNVs can be distinguished into classic and occult subtypes, which are characterized by variable natural history and different responsiveness to some therapeutic procedures. At present, the dramatic vision loss due to CNV can be mainly treated by two interventional strategies, which are utilizable in either single or combined modalities: photodynamic therapy with verteporfin (PDT-V), and intravitreal administration of drugs acting against vascular endothelial growth factor. The combined use of PDT-V and anti-angiogenic drugs represents one of the most promising strategies against neovascular macular degeneration, but it unavoidably results in an expensive increase in health resource utilization. However, the positive data from several studies serve as a basis for reconsidering the role of PDT-V, which has undergone a renaissance prompted by the need for a more rational therapeutic approach toward CNV. New pharmacogenetic knowledge of PDT-V points to exploratory prospects to optimize the clinical application of this intriguing photothrombotic procedure. In fact, a Medline search provides data regarding the role of several single nucleotide polymorphisms (SNPs) as genetic predictors of CNV responsiveness to PDT-V. Specifically, correlations between SNPs and different levels of PDT-V efficacy have been detected by examining the gene variants influencing (i) thrombo-coagulative pathways, i.e. methylenetetrahydrofolate reductase (MTHFR) 677C>T (rs1801133), factor V (F5) 1691G>A (rs6025), prothrombin (F2) 20210G>A (rs1799963), and factor XIII-A (F13A1) 185G>T (rs5985); (ii) complement activation andor inflammatory processes, i.e. complement factor H (CFH) 1277T>C (rs1061170), high-temperature requirement factor A1 (HTRA1) promoter -512G>A (rs11200638), and two variants of the C-reactive protein (CRP) gene (rs2808635 and rs876538); and (iii) production and bioavailability of vascular endothelial growth factor (VEGFA -2578C>A rs699947 and rs2146323). This article critically evaluates both the clinical plausibility and the opportunity to utilize the most important SNP-response interactions of PDT-V for an effective upgrade of the current anti-CNV therapeutic scenario. In addition, the pharmacogenetics of a very severe post-PDT-V adverse event, i.e. a decrease in acute vision, is briefly discussed. A comprehensive appraisal of the findings reviewed in this article should be carefully considered to design future trials aimed at verifying (after proper genotypic stratification of the enrolled patients) whether these innovative pharmacogenetic approaches will be able to improve the multifaceted interventional management of neovascular macular degeneration.

UR - http://www.scopus.com/inward/record.url?scp=80052701489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052701489&partnerID=8YFLogxK

U2 - 10.2165/11592270-000000000-00000

DO - 10.2165/11592270-000000000-00000

M3 - Article

C2 - 21913742

AN - SCOPUS:80052701489

VL - 15

SP - 195

EP - 210

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

SN - 1177-1062

IS - 4

ER -